Temporal trends in gastrointestinal bleeding associated with percutaneous coronary intervention: analysis of the 1998-2006 Nationwide Inpatient Sample (NIS) database.

[1]  Michele Voeltz,et al.  Anemia, hemorrhage, and transfusion in percutaneous coronary intervention, acute coronary syndromes, and ST-segment elevation myocardial infarction. , 2009, The American journal of cardiology.

[2]  S. Sawada,et al.  Upper gastrointestinal bleeding in patients receiving dual antiplatelet therapy after coronary stenting. , 2009, Internal medicine.

[3]  E. Topol,et al.  Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. , 2003, JAMA.

[4]  S. Yusuf,et al.  Adverse Impact of Bleeding on Prognosis in Patients With Acute Coronary Syndromes , 2006, Circulation.

[5]  P. R. R. Ecurrent,et al.  EFFECTS OF CLOPIDOGREL IN ADDITION TO ASPIRIN IN PATIENTS WITH ACUTE CORONARY SYNDROMES WITHOUT ST-SEGMENT ELEVATION , 2001 .

[6]  B. Strauss,et al.  Predictors and 1-year outcome of major bleeding in patients with non-ST-elevation acute coronary syndromes: insights from the Canadian Acute Coronary Syndrome Registries. , 2005, American heart journal.

[7]  R. D'Agostino.  Adjustment Methods: Propensity Score Methods for Bias Reduction in the Comparison of a Treatment to a Non‐Randomized Control Group , 2005 .

[8]  W. Rogers,et al.  Trends in quality of care for patients with acute myocardial infarction in the National Registry of Myocardial Infarction from 1990 to 2006. , 2008, American heart journal.

[9]  V. Wong,et al.  Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. , 2005, The New England journal of medicine.

[10]  S. Steinhubl,et al.  Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: Insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. , 2009, American heart journal.

[11]  L. Grines,et al.  Incidence and prognostic impact of gastrointestinal bleeding after percutaneous coronary intervention for acute myocardial infarction. , 2005, The American journal of cardiology.

[12]  E. Antman,et al.  Prasugrel versus clopidogrel in patients with acute coronary syndromes. , 2007, The New England journal of medicine.

[13]  M. Al-mallah,et al.  Predictors and outcomes associated with gastrointestinal bleeding in patients with acute coronary syndromes , 2007, Journal of Thrombosis and Thrombolysis.

[14]  P. Foley,et al.  Clinical review: gastrointestinal bleeding after percutaneous coronary intervention: a deadly combination. , 2008, QJM : monthly journal of the Association of Physicians.

[15]  G. Stone,et al.  Gastrointestinal bleeding in percutaneous coronary intervention and acute coronary syndromes. , 2009, The American journal of cardiology.

[16]  E. Topol,et al.  Predictors and impact of major hemorrhage on mortality following percutaneous coronary intervention from the REPLACE-2 Trial. , 2007, The American journal of cardiology.

[17]  Adelaide,et al.  Bivalirudin for patients with acute coronary syndromes. , 2006, The New England journal of medicine.

[18]  B. Gersh,et al.  Bivalirudin during primary PCI in acute myocardial infarction. , 2008, The New England journal of medicine.

[19]  Robert M Califf,et al.  A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes. , 2006, Journal of the American College of Cardiology.

[20]  Werner Klein,et al.  Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE) , 2003 .

[21]  A. Yan,et al.  Temporal trend of in-hospital major bleeding among patients with non ST-elevation acute coronary syndromes. , 2010, American heart journal.

[22]  H. White,et al.  Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY Trial. , 2007, Journal of the American College of Cardiology.

[23]  J. Messenger,et al.  Treatments, trends, and outcomes of acute myocardial infarction and percutaneous coronary intervention. , 2010, Journal of the American College of Cardiology.

[24]  S. Yusuf,et al.  The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme; rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease. , 2000, European heart journal.

[25]  W. Baine,et al.  The Agency for Healthcare Research and Quality , 2006, Italian Journal of Public Health.

[26]  R. Califf,et al.  Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. , 2005, The American journal of cardiology.

[27]  B. C. Wong,et al.  Gastrointestinal Bleeding in Patients Receiving a Combination of Aspirin, Clopidogrel, and Enoxaparin in Acute Coronary Syndrome , 2008, The American Journal of Gastroenterology.

[28]  Sunil V. Rao,et al.  Bleeding in Patients Undergoing Percutaneous Coronary Intervention: The Development of a Clinical Risk Algorithm From the National Cardiovascular Data Registry , 2009, Circulation. Cardiovascular interventions.

[29]  H. White,et al.  Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: study design and rationale. , 2004, American heart journal.

[30]  H. White,et al.  Gastrointestinal bleeding in patients with acute coronary syndromes: incidence, predictors, and clinical implications: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. , 2009, Journal of the American College of Cardiology.